AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data

Head-To-Head Trial Of The Two IL-5 Inhibitors

12 Sep 2023

AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.

Race_Horse — AstraZeneca goes head-to-head with GSK in EPGA • Source: Shutterstock

AstraZeneca PLC could soon have another indication to add to severe asthma for its respiratory blockbuster Fasenra after presenting data from a late-stage trial for eosinophilic granulomatosis with polyangiitis (EGPA).

The UK drugs major has posted positive high-level results from the MANDARA Phase III trial which show that Fasenra (benralizumab),...